OSUR

Business Context and Reporting Period

Company: OraSure Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2005
Business Overview: The company develops, manufactures, and markets oral fluid specimen collection devices, diagnostic products (including HIV and drug testing), and cryosurgical medical devices. Key products include OraQuick (rapid HIV test), Intercept (drug testing), and Histofreezer/Freeze Off (cryosurgery).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 28% in Q3 and 29% for the nine-month period compared to 2004. This was driven primarily by a 90% increase in infectious disease testing sales (OraQuick) and a 31% increase in substance abuse testing sales (Intercept).
• Profitability Turnaround: The company reported net income of $3.8 million for Q3 and $6.8 million for the nine-month period, a significant improvement from net losses of $0.3 million in the comparable 2004 periods.
• Asset Impairment: A $1.5 million charge was recorded in June 2005 related to the UP link product (inventory and fixed assets) after failing to find a distribution outlet. This reduced gross margin for the nine-month period.
• Customer Concentration: The top three customers accounted for 38% of Q3 2005 revenues (down from 41% in Q3 2004), indicating a slight reduction in concentration risk.
• Legal Expenses: General and administrative expenses increased due to legal fees associated with patent litigation against Schering-Plough ($0.65 million in Q3 2005 vs. $0.46 million in Q3 2004).

Guidance, Outlook, and Risks

• Product Launches: The company is pursuing CE marking for OraQuick ADVANCE to enable European sales in 2006. International OTC cryosurgery products are expected to launch in additional European countries and Australia/New Zealand in early 2006.
• Market Outlook: Management expects continued growth in Intercept sales as customers shift from urine to oral fluid testing. However, sales in the insurance risk assessment market are expected to decline in 2005 due to reduced life insurance application activity.
• Tax Position: The company utilized Net Operating Loss (NOL) carryforwards to offset income taxes, resulting in no tax provision. Management expects to complete a Section 382 analysis in Q4 2005 to determine if ownership changes limit NOL usage. A release of the deferred tax valuation allowance is anticipated if sustained profitability is demonstrated.
• Key Risks:
  • Litigation: Ongoing patent infringement lawsuit against Schering-Plough regarding cryosurgical technology.
  • Competition: Increasing competition in the rapid HIV testing market from competitors like Ortho Diagnostics, Bio-Rad, and Trinity Biotech.
  • Supply Chain: Reliance on sole-source providers for critical components of OraQuick and OraSure products.
  • Regulatory: Pending finalization of SAMHSA guidelines for oral fluid drug testing, which may require product modifications.

Investor Verification Checklist

• Section 382 Analysis: Verify the outcome of the Q4 2005 analysis regarding ownership changes and the potential release of the deferred tax valuation allowance.
• CE Marking Status: Confirm the timeline and success of obtaining CE marking for OraQuick ADVANCE to validate the 2006 European launch strategy.
• Schering-Plough Litigation: Monitor court rulings on summary judgment motions and potential impact on damages or injunctions.
• Customer Concentration: Review the financial health of the top three customers (Medtech, Lab One, Abbott) which collectively represent a significant portion of revenue.
• UP Link Termination: Confirm the formal termination of agreements with Dräger Safety and the final disposition of remaining assets.